Analysts Are Bullish on These Healthcare Stocks: Cerecor Inc (CERC), Co-Diagnostics Inc (CODX)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cerecor Inc (CERC) and Co-Diagnostics Inc (CODX) with bullish sentiments.

Cerecor Inc (CERC)

Maxim Group analyst Caroline Palomeque initiated coverage with a Buy rating on Cerecor Inc today and set a price target of $10. The company’s shares closed yesterday at $5.19.

Palomeque commented:

“We are initiating coverage of Cerecor, Inc. with a Buy rating and a $10 price target. The company is under new management, which has made acquisitions to bring in revenue-generating products while it develops its potentially high- value assets in Parkinson’s disease (PD) and rare pediatric diseases.”

According to TipRanks.com, Palomeque has 0 stars on 0-5 star ranking scale with an average return of -4.3% and a 45.7% success rate. Palomeque covers the Healthcare sector, focusing on stocks such as VistaGen Therapeutics, AzurRx BioPharma Inc, and Oxford BioMedica plc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cerecor Inc with a $10 average price target, a 92.7% upside from current levels. In a report issued on April 1, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $11 price target.

See today’s analyst top recommended stocks >>

Co-Diagnostics Inc (CODX)

In a report released today, Jason McCarthy from Maxim Group initiated coverage with a Buy rating on Co-Diagnostics Inc and a price target of $2. The company’s shares closed yesterday at $1.07, close to its 52-week low of $0.90.

McCarthy noted:

“We are initiating coverage of Co-Diagnostics (CDI) Inc. with a Buy rating and $2 price target. CDI’s unique CoPrimer technology could potentially solve the polymerase chain reaction (PCR) primer dimer (P-D) problem, simplify multiplexing (including SNP detection), and integrate into the infectious disease (ID), agriculture, and liquid biopsy testing spaces.”

According to TipRanks.com, McCarthy has currently no stars on a ranking scale of 0-5 stars, with an average return of -6.9% and a 35.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Co-Diagnostics Inc with a $2 average price target, implying an 86.9% upside from current levels. In a report issued on April 3, H.C. Wainwright also reiterated a Buy rating on the stock with a $2 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts